Evidence map›Paper›PMID 14500366›Full record

ArticleCancer research2003

Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.

Angelo Agathanggelou, Ivan Bièche, Jalal Ahmed-Choudhury, Barbara Nicke, Reinhard Dammann, Shairaz Baksh, Boning Gao, John D Minna, Julian Downward, Eamonn R Maher and 1 more

Abstract readComparative Study
In one paragraph

Article in Cancer research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. The Role of RASSF1C in the Tumor Microenvironment.Current issues in molecular biology · 2023
    Article
  5. The Epigenetic Landscape of Meningiomas.Advances in experimental medicine and biology · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Menin determines K-RAS proliferative outputs in endocrine cells.The Journal of clinical investigation · 2014
    Article
  17. Article
  18. Article
  19. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Angelo AgathanggelouSection of Medical and Molecular Genetics, Division of Reproductive and Child Health, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Ivan Bièche
Jalal Ahmed-Choudhury
Barbara Nicke
Reinhard Dammann
Shairaz Baksh
Boning Gao
John D Minna
Julian Downward
Eamonn R Maher
Farida Latif
University of Birmingham · GBCancer Research UK · GBHôpital René Huguenin · FRLuther University · KR

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
HUMAN 3P RECESSIVE ONCOGENESR01CA071618 · NCI · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI MINNA, JOHN D · 1996 to 2004
$1.4M
NCI NIH HHS CA71618NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA70907NCI NIH HHS R01 CA071618Wellcome Trust
6 · The paper itself

Abstract

RASSF1A is a recently identified 3p21.3 tumor suppressor gene. The high frequency of epigenetic inactivation of this gene in a wide range of human sporadic cancers including non-small cell lung cancer (NSCLC) and neuroblastoma suggests that RASSF1A inactivation is important for tumor development. Although little is known about the function of RASSF1A, preliminary data suggests that it may have multiple functions. To gain insight into RASSF1A functions in an unbiased manner, we have characterized the expression profile of a lung cancer cell line (A549) transfected with RASSF1A. Initially we demonstrated that transient expression of RASSF1A into the NSCLC cell line A549 induced G(1) cell cycle arrest, as measured by propidium iodide staining. Furthermore, annexin-V staining showed that RASSF1A-expressing cells had an increased sensitivity to staurosporine-induced apoptosis. We then screened a cDNA microarray containing more than 6000 probes to identify genes differentially regulated by RASSF1A. Sixty-six genes showed at least a 2-fold change in expression. Among these were many genes with relevance to tumorigenesis involved in transcription, cytoskeleton, signaling, cell cycle, cell adhesion, and apoptosis. For 22 genes we confirmed the microarray results by real-time RT-PCR and/or Northern blotting. In silico, we were able to confirm the majority of these genes in other NSCLC cell lines using published data on gene expression profiles. Furthermore, we confirmed 10 genes at the RNA level in two neuroblastoma cell lines, indicating that these RASSF1A target genes have relevance in non-lung cell backgrounds. Protein analysis of six genes (ETS2, Cyclin D3, CDH2, DAPK1, TXN, and CTSL) showed that the changes induced by RASSF1A at the RNA level correlated with changes in protein expression in both non-small cell lung cancer and neuroblastoma cell lines. Finally, we have used a transient assay to demonstrate the induction of CDH2 and TGM2 by RASSF1A in NSCLC cell lines. We have identified several novel targets for RASSF1A tumor suppressor gene both at the RNA and the protein levels in two different cellular backgrounds. The identified targets are involved in diverse cellular processes; this should help toward understanding mechanisms that contribute to RASSF1A biological activity.

Indexed as

Tumor Suppressor ProteinsApoptosisCarcinoma, Non-Small-Cell LungCyclin D1Down-RegulationG1 PhaseGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansLung NeoplasmsNeoplasm ProteinsNeuroblastomaOligonucleotide Array Sequence AnalysisReverse Transcriptase Polymerase Chain ReactionStaurosporineCyclin D1Neoplasm ProteinsRASSF1 protein, humanStaurosporineTumor Suppressor Proteins

Identifiers

PMID14500366
PMCPMC3484890
OpenAlexW1763011611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.